We have previously reported, in a small study of BRCA1-positive women with early breast cancer, that a high rate of complete pathologic response was achieved using cisplatin chemotherapy as a single agent in the neo-adjuvant setting [13]. This evidence concerns the gene BRCA1 and breast carcinoma.